|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:2001
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Kineret
|
|
gptkbp:chemical_formula
|
C_14 H_19 N_3 O_5 S
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
long-term management
acute flares
|
|
gptkbp:contraindication
|
active infections
hypersensitivity to anakinra
|
|
gptkbp:developed_by
|
gptkb:Amgen
|
|
gptkbp:dosage_form
|
solution for injection
|
|
gptkbp:financial_stability
|
refrigerated storage
|
|
gptkbp:formulation
|
lyophilized powder
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Anakinra
|
|
gptkbp:indication
|
gptkb:systemic_juvenile_idiopathic_arthritis
osteoarthritis
gout
|
|
gptkbp:interacts_with
|
live vaccines
other immunosuppressants
|
|
gptkbp:invention
|
patented
generic available
|
|
gptkbp:is_monitored_by
|
liver function tests
complete blood count
infection signs
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
IL-1 receptor antagonist
|
|
gptkbp:patient_population
|
gptkb:children
adults
|
|
gptkbp:pharmaceutical_class
|
anti-inflammatory agent
cytokine inhibitor
|
|
gptkbp:pharmacokinetics
|
half-life of approximately 4-6 hours
|
|
gptkbp:price
|
varies by region
insurance coverage may apply
|
|
gptkbp:research_areas
|
autoimmune diseases
chronic diseases
pain management
inflammatory diseases
|
|
gptkbp:route_of_administration
|
subcutaneous
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
headache
nausea
abdominal pain
infections
injection site reactions
thrombocytopenia
neutropenia
elevated liver enzymes
|
|
gptkbp:targets
|
interleukin-1
|
|
gptkbp:used_for
|
gptkb:rheumatoid_arthritis
cryopyrin-associated periodic syndromes
|
|
gptkbp:bfsParent
|
gptkb:EMD_Serono
|
|
gptkbp:bfsLayer
|
5
|